Car-T is named as an intervention in 11 current clinical trials in our China register. 7 are recruiting patients now. The most common phase is Phase 1. The sponsor with the most trials is Institute of Hematology & Blood Diseases Hospital, China (2). The most-studied condition is Multiple Myeloma.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT
NCT07441291 · ClinicalTrials.gov ↗ · B ALL, Allogenetic Hematopoietic Stem Cell Transplantation, MRD-positive
|
Phase 3 | Recruiting | Peking University People's Hospital | China |
|
Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell Lymphoma
NCT06996132 · ClinicalTrials.gov ↗ · Relapsed or Refractory Aggressive B-cell Lymphoma
|
Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | China |
|
Clinical Study on the Safety and Efficacy of BCMA-CART±ASCT in Treating Young Multiple Myeloma Patients
NCT07169500 · ClinicalTrials.gov ↗ · Multiple Myeloma
|
Phase 1/2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | China |
|
CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study
NCT06136364 · T-lymphoblastic Lymphoma, T-ALL
|
Phase 1 | Recruiting | Hebei Senlang Biotechnology Inc., Ltd. | China |
|
Safety and Efficacy of Fourth-Generation CAR-T in the Treatment of Hematologic Malignancies
NCT06758713 · ClinicalTrials.gov ↗ · Multiple Myeloma, B-cell Lymphoma, Hematological Malignancy
|
Phase 1 | Recruiting | The Third Affiliated Hospital of Southern Medical University | China |
|
To Observe the CD7-targeted CAR-T Therapy in the Treatment of r/r PTCL
NCT07143929 · ClinicalTrials.gov ↗ · CD7 Positive R/R PTCL
|
Phase 1 | Recruiting | Peking University People's Hospital | China |
|
Predictive Factors for the Efficacy of CD19 CAR-T Therapy in Relapsed/Refractory Large B-Cell Lymphoma: A Clinical Study
NCT07236203 · ClinicalTrials.gov ↗ · Large B-Cell Lymphoma
|
Observational | Recruiting | Fudan University | China |
|
ARTA-based Chemo-free Bridging/Maintenance Therapy in CAR-T Treatment for High-Risk R/R B-NHL Ineligible for HDCT and ASCT
NCT06646666 · ClinicalTrials.gov ↗ · B-cell Non Hodgkin Lymphoma
|
Phase 2 | Not yet open | Ruijin Hospital | China |
|
Comparing ASCT Followed by Anti-BCMA CAR-T vs. ASCT Alone in NDMM Patients Eligible for ASCT
NCT06963866 · ClinicalTrials.gov ↗ · Multiple Myeloma, Newly Diagnosed
|
Phase 2 | Not yet open | Xuzhou Medical University | China |
|
Clinical Study of Anti-CLL1-CD33-NKG2D Bicephali CAR-T for Relapsed/Refractory Acute Myeloid Leukemia
NCT07370064 · ClinicalTrials.gov ↗ · AML (Acute Myeloid Leukemia)
|
Phase 1/2 | Not yet open | Xuzhou Medical University | China |
|
A Clinical Study Exploring Universal CAR-T Cell in Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
NCT07043218 · ClinicalTrials.gov ↗ · B-cell Acute Lymphoblastic Leukemia
|
Phase 1 | Not yet open | Shanghai Tongji Hospital, Tongji University School of Medicine | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Multiple Myeloma | 2 |
| T-lymphoblastic Lymphoma | 1 |
| T-ALL | 1 |
| AML (Acute Myeloid Leukemia) | 1 |
| Large B-Cell Lymphoma | 1 |
| B ALL | 1 |
| Allogenetic Hematopoietic Stem Cell Transplantation | 1 |
| MRD-positive | 1 |
| CD7 Positive R/R PTCL | 1 |
| B-cell Non Hodgkin Lymphoma | 1 |
| Multiple Myeloma, Newly Diagnosed | 1 |
| Relapsed or Refractory Aggressive B-cell Lymphoma | 1 |
| B-cell Acute Lymphoblastic Leukemia | 1 |
| B-cell Lymphoma | 1 |
| Hematological Malignancy | 1 |
| Lead sponsor | Trials |
|---|---|
| Institute of Hematology & Blood Diseases Hospital, China | 2 |
| Xuzhou Medical University | 2 |
| Peking University People's Hospital | 2 |
| Hebei Senlang Biotechnology Inc., Ltd. | 1 |
| Fudan University | 1 |
| Ruijin Hospital | 1 |
| Shanghai Tongji Hospital, Tongji University School of Medicine | 1 |
| The Third Affiliated Hospital of Southern Medical University | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 11 | 7 |
A trial with sites in more than one country appears in each of those registers.
11 current trials in our China register name Car-T as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 7 of the 11 trials are recruiting: 7 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Institute of Hematology & Blood Diseases Hospital, China (2), Xuzhou Medical University (2), Peking University People's Hospital (2) and Hebei Senlang Biotechnology Inc., Ltd (1), among 8 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Car-T works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Car-T works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Car-T (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.